These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 15373969)
81. Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides. Wang Y; Krieg AM Vaccine; 2004 Jun; 22(20):2641-50. PubMed ID: 15193390 [TBL] [Abstract][Full Text] [Related]
82. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release. Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412 [TBL] [Abstract][Full Text] [Related]
83. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228 [TBL] [Abstract][Full Text] [Related]
84. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice. Brummel R; Roberts TL; Stacey KJ; Lenert P Eur J Immunol; 2006 Jul; 36(7):1951-62. PubMed ID: 16791898 [TBL] [Abstract][Full Text] [Related]
85. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. Yasuda K; Ogawa Y; Yamane I; Nishikawa M; Takakura Y J Leukoc Biol; 2005 Jan; 77(1):71-9. PubMed ID: 15496451 [TBL] [Abstract][Full Text] [Related]
86. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. Marshak-Rothstein A; Busconi L; Lau CM; Tabor AS; Leadbetter EA; Akira S; Krieg AM; Lipford GB; Viglianti GA; Rifkin IR J Endotoxin Res; 2004; 10(4):247-51. PubMed ID: 15373969 [TBL] [Abstract][Full Text] [Related]
87. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9. Schetter C; Vollmer J Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254 [TBL] [Abstract][Full Text] [Related]
88. TLR9 in health and disease. Vollmer J Int Rev Immunol; 2006; 25(3-4):155-81. PubMed ID: 16818370 [TBL] [Abstract][Full Text] [Related]
90. Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression. Griebel PJ; Brownlie R; Manuja A; Nichani A; Mookherjee N; Popowych Y; Mutwiri G; Hecker R; Babiuk LA Vet Immunol Immunopathol; 2005 Oct; 108(1-2):11-6. PubMed ID: 16098606 [TBL] [Abstract][Full Text] [Related]
91. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Daubenberger CA Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401 [TBL] [Abstract][Full Text] [Related]
92. Toll-like receptors and activation of autoreactive B cells. Leadbetter EA; Rifkin IR; Marshak-Rothstein A Curr Dir Autoimmun; 2003; 6():105-22. PubMed ID: 12408049 [No Abstract] [Full Text] [Related]
93. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Verthelyi D; Zeuner RA Trends Immunol; 2003 Oct; 24(10):519-22. PubMed ID: 14552833 [TBL] [Abstract][Full Text] [Related]